Quantum algorithms for chemistry and life sciences

Algorithmiq, IBM and Cleveland Clinic are pioneering the development of breakthrough quantum chemistry approaches to rationalise and optimise photo-sensitiser drugs for clinical use in photodynamic cancer therapy.

With Algorithmiq’s state-of-the-art drug discovery platform, Aurora, IBM’s world-class quantum hardware and Cleveland Clinic’s extensive experience in the relevant pharma applications, the partnership aims to demonstrate quantum advantage for a photo-chemistry driven quantum application in drug discovery and development.

Algorithmiq has entered into a partnership with Quantum Circuits Inc (QCI) to investigate the reaction rate of the enzyme aldehyde oxidase (AO) in order to accurately predict AO-mediated drug metabolism. QCI’s hardware possesses a unique qubit architecture which incorporates error detection, a key ingredient for error correction, and together with our proprietary error mitigation technique, we aim to set the foundations for the transition towards early fault tolerance era.

In a forward-thinking collaboration, Algorithmiq and Cleveland Clinic are bringing together their strengths to advance medical science through quantum network medicine. By merging Algorithmiq’s expertise in quantum computation with Cleveland Clinic’s leadership in clinical neurophysiology, we go beyond Artificial Intelligence-enabled methods. We apply quantum-inspired algorithms to reveal networks of brain activity, aiming to achieve a deeper mechanistic understanding of neurocognitive outcomes after brain surgery for epilepsy. This partnership embodies our shared commitment to bridging the gap between the frontiers of science and patient care.